The Conversation (0)
Akari Therapeutics announced the appointment of Dr. David Horn Solomon as CEO starting on August 28.
Akari Therapeutics (NASDAQ:AKTX) announced the appointment of Dr. David Horn Solomon as CEO starting on August 28.
As quoted in the press release:
“I am very pleased that David will be joining Akari and that we have been successful in attracting a person of his calibre, with over 20 years of leadership experience in the biotechnology industry,” said Ray Prudo, M.D., Executive Chairman of Akari. “David has a strong track record of leading Phase 2-stage companies like Akari. most notably, at Zealand Pharma where he led the development of lixisenatide, which is now commercialized by Sanofi.”
Akari is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by the dysregulation of complement C5 and/or leukotriene B4 (LTB4).
Click here to read the full press release.
Source: globenewswire.com